Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease
Overview
Authors
Affiliations
Unlabelled: Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in affluent countries. Accurate noninvasive tests for liver injury are urgently needed. The aim of this study was to evaluate the accuracy of transient elastography for the diagnosis of fibrosis and cirrhosis in patients with NAFLD and to study factors associated with discordance between transient elastography and histology. Two hundred forty-six consecutive patients from two ethnic groups had successful liver stiffness measurement and satisfactory liver biopsy specimens. The area under the receiver-operating characteristics curve (AUROC) of transient elastography for F3 or higher and F4 disease was 0.93 and 0.95, respectively, and was significantly higher than that of the aspartate aminotransferase-to-alanine aminotransferase ratio, aspartate aminotransferase-to-platelet ratio index, FIB-4, BARD, and NAFLD fibrosis scores (AUROC ranged from 0.62 to 0.81, P < 0.05 for all comparisons). At a cutoff value of 7.9 kPa, the sensitivity, specificity, and positive and negative predictive values for F3 or greater disease were 91%, 75%, 52%, and 97%, respectively. Liver stiffness was not affected by hepatic steatosis, necroinflammation, or body mass index. Discordance of at least two stages between transient elastography and histology was observed in 33 (13.4%) patients. By multivariate analysis, liver biopsy length less than 20 mm and F0-2 disease were associated with discordance.
Conclusion: Transient elastography is accurate in most NAFLD patients. Unsatisfactory liver biopsy specimens rather than transient elastography technique account for most cases of discordance. With high negative predictive value and modest positive predictive value, transient elastography is useful as a screening test to exclude advanced fibrosis. Liver biopsy may be considered in NAFLD patients with liver stiffness of at least 7.9 kPa.
The Value of Clinical Decision Support in Healthcare: A Focus on Screening and Early Detection.
Schafer H, Lajmi N, Valente P, Pedrioli A, Cigoianu D, Hoehne B Diagnostics (Basel). 2025; 15(5).
PMID: 40075895 PMC: 11899545. DOI: 10.3390/diagnostics15050648.
Distinct metabolic perturbations link liver steatosis and incident CVD in lean but not obese PWH.
van Eekeren L, Vadaq N, Blaauw M, Groenendijk A, Vos W, Nelwan E BMC Med. 2025; 23(1):78.
PMID: 39934780 PMC: 11817758. DOI: 10.1186/s12916-025-03914-5.
Cano Contreras A, Del Rocio Francisco M, Vargas Basurto J, Gonzalez-Gomez K, Amieva-Balmori M, Roesch Dietlen F World J Hepatol. 2025; 17(1):101704.
PMID: 39871906 PMC: 11736477. DOI: 10.4254/wjh.v17.i1.101704.
Chien S, Chiu H, Chiu Y, Wang R, Dillera K, Lee K Dig Dis Sci. 2025; .
PMID: 39826065 DOI: 10.1007/s10620-025-08844-z.
Ram R, Subramanian A, K R J Int Assoc Provid AIDS Care. 2025; 24():23259582241311912.
PMID: 39801172 PMC: 11726528. DOI: 10.1177/23259582241311912.